University of Texas MD Anderson Cancer Center

Response Assessment in Neuro-Oncology (RANO) 2009–2025: Broad scope and implementation—A progress report (2025) Van den Bent MJ, Vogelbaum MA, Cloughesy T, Galldiks N, Albert NL, Tonn JC, Avila E, et al. Journal article, Review article Ovarian cancer risk and survival according to tumor sex hormone receptor expression: An ovarian Cancer association consortium and ovarian tumor tissue analysis consortium pooled analysis (2025) Fu Z, Borho L, Taylor SE, Kelemen LE, DeFazio A, Webb PM, Köbel M, et al. Journal article Health-Related Quality of Life in Patients with HR+/HER2- Early Breast Cancer Treated with Ribociclib Plus a Nonsteroidal Aromatase Inhibitor: Results from the NATALEE Trial (2025) Fasching P, Slamon D, Nowecki Z, Kukielka-Budny B, Stroyakovskiy D, Yardley DA, Huang CS, et al. Journal article Change of the guards—Looking back at Michael Droller: Visionary and supporter—The perspective of the International Bladder Cancer Network (2025) Schmitz-Dräger B, Grossmann HB, Goebell P, Kamat AM, Black PC Journal article A phase III trial of adjuvant ribociclib plus endocrine therapy versus endocrine therapy alone in patients with HR-positive/HER2-negative early breast cancer: final invasive disease-free survival results from the NATALEE trial (2025) Hortobagyi GN, Lacko A, Sohn J, Cruz F, Ruiz Borrego M, Manikhas A, Hee Park Y, et al. Journal article Joint ABS/GEC-ESTRO Consensus Statement on the objectives of training in brachytherapy for physicians (2025) Keyes M, Sturdza AE, Crook J, Anderson B, Boldrini L, Chino J, Corradini S, et al. Journal article Neoadjuvant or perioperative therapy for melanoma metastasis in clinical practice: an international survey. (2025) Hauschild A, Garbe C, Ascierto PA, Demidov L, Dreno B, Dummer R, Eggermont A, et al. Journal article A Preoperative Window-of-Opportunity Study of Oral SERD, Imlunestrant, in Newly Diagnosed ER-Positive, HER2-Negative Early Breast Cancer: Results from the EMBER-2 Study (2024) Neven P, Stahl N, Vidal M, Martín M, Kaufman PA, Harbeck N, Hunt KK, et al. Journal article A brave new framework for glioma drug development (2024) Hotchkiss KM, Karschnia P, Schreck KC, Geurts M, Cloughesy TF, Huse J, Duke ES, et al. Journal article, Review article 177Lu]Lu-DOTA-TATE plus long-acting octreotide versus high‑dose long-acting octreotide for the treatment of newly diagnosed, advanced grade 2-3, well-differentiated, gastroenteropancreatic neuroendocrine tumours (NETTER-2): an open-label, randomised, phase 3 study (2024) Singh S, Halperin D, Myrehaug S, Herrmann K, Pavel ME, Kunz PL, Chasen B, et al. Journal article